30 September 2026

Oncoinvent ASA – New share capital registered

Reference is made to the stock exchange announcement made by Oncoinvent ASA (the “Company“) on 22 September 2026 regarding the successful private placement of 1,531,000 new shares (the “Private Placement“), divided on a first tranche of 990,689 shares (“Tranche 1“) and a second tranche of 540,311 shares (“Tranche 2“), and the allocation of 119,000 new shares in a retail offering carried out via Nordnet (the “Retail Offering“).

The share capital increase pertaining to the issuance of the in total 1,650,000 new shares in the Private Placement and Retail Offering (the “New Shares“) has now been registered with the Norwegian Register of Business Enterprises. The Company’s new share capital is NOK 1,532,103 divided on 6,128,412 shares, each with a par value of NOK 0.25.

895,681 of the New Shares will be issued on the Company’s existing ISIN and will hence be admitted to trading as soon as they have been issued in the VPS. The remaining 754,319 New Shares will be issued on a separate, temporary ISIN pending approval by the Norwegian Financial Supervisory Authority (Norwegian: Finanstilsynet) of a listing prospectus. The New Shares delivered on the separate, temporary ISIN will thus not be listed or tradeable on Euronext Oslo Børs until such listing prospectus has been approved and published, expected during Q4 2026.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com



Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close